Dealing with FCPA and Other Investigations Under the New Normal – Webinar Recording/Transcript
Dealing with FCPA and Other Investigations Under the New Normal
Want to attend the live webinar on June 16? Click here to register.
Is your business continuing to function during the COVID-19 pandemic? Has your organization halted operations but plans to reopen soon? Are you wondering how to safely mitigate your risks during this trying period while avoiding investigations from regulatory bodies?
The economic disruptions of the COVID-19 crisis have brought unprecedented stressors to drug and device manufacturers, and your team will need to navigate these complications without relying on actions that may be deemed uncompliant. These obstacles inevitably create incentives and opportunities for fraud — but requirements under the Foreign Corrupt Practices Act of 1977 (FCPA) and other relevant regulations are as critical as ever. Regulators will be expecting companies to foresee potential risk factors and manage them accordingly.
Avoid falling into risky patterns or processes while operating under this new normal. Instead, learn how to adjust your business practices and guard your supply chain against compliancy issues through this detailed FDAnews webinar.
Gail Rodgers and Nancy Sims, attorneys with DLA Piper, will share practical guidelines and tips on maintaining compliance during these shifting and complex times, while also discussing how to manage any potential investigations from regulatory bodies.
Key Presentation Takeways:
- Identifying Concerns and Risk
- Remote workforce
- Reopening business
- Compensating for disrupted controls
- Remote working procedures
- Alternative working arrangement processes
- “Pressure testing” for compliance
- Remote financial controls
- Applying a risk-based approach
The COVID-19 crisis has brought extraordinary strains to business practices and compliant supply chains. Ensure your organization is protected before and during an investigation.
Meet Your Presenters:
Gail Rodgers, a partner at DLA Piper, has spent the majority of her career representing multinational pharmaceutical and medical device companies. Rodgers focuses her practice on end-to-end compliance and investigations, including those around bribery and corruption. She has represented multiple Fortune 500 companies in cross-border and multijurisdictional investigations involving allegations of violations of the Foreign Corrupt Practices Act and the UK Bribery Act. She has extensive experience leading teams for corporate internal and government investigations across the globe. Rodgers also conducts proactive global compliance reviews and partners with businesses in implementing controls and remediations and evaluating the efficacy of compliance and investigation programs and protocols. She has a deep scientific background and has represented multiple pharmaceutical and medical device clients in products liability multi-district litigation. She is also the Chair of the DRI Drug and Medical Device Committee.
Nancy Sims, of counsel at DLA Piper, is a commercial litigator who focuses on complex business disputes and investigations. Sims has extensive experience conducting corporate internal investigations and government investigations, including those implicating the Foreign Corrupt Practices Act, UK Bribery Act, and False Claims Act. In addition, her litigation practice involves defending class actions in the consumer, franchise, labor and employment, and insurance spaces. Sims has successfully represented clients in commercial matters based on contract claims, unfair competition, false advertising, fraud, and related business torts. She also serves as the Chair of the Diversity and Inclusion Committee of DLA Piper's Los Angeles Offices and is a member of DLA Piper's North American Pro Bono Committee.
Who Will Benefit:
- Pharmaceutical, medical device, or biopharma staff with global practices
- Compliance personnel
- Audit committees focused on compliance and investigations